Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) announced on Tuesday that it has entered into a new stock purchase agreement with an institutional investor, allowing the company to issue and sell up to $14,591,939 of its common stock. The agreement was executed on November 26, as disclosed in a press release statement and detailed in a recent SEC filing. Currently trading at $0.07 per share with a market capitalization of just $1.48 million, InvestingPro analysis suggests the stock is trading below its Fair Value, despite facing significant financial challenges.
This new agreement is a continuation of the company’s existing equity line program. Under previous agreements signed in February 2024, November 2024, and July 2025, Cero Therapeutics sold a combined total of 12,612,270 shares of common stock for aggregate proceeds of approximately $10.4 million. The new agreement is designed to enable the company and the investor to reach a cumulative total of $25 million in stock issuances under the program.
According to the filing, Cero Therapeutics may, at its discretion, direct the investor to purchase shares on any business day when the closing sale price of the common stock is at least $0.02 per share. Individual purchase requests cannot exceed 10,000 shares or $100,000 per transaction. Additionally, the agreement allows for larger aggregate purchases—up to $10 million—through VWAP (volume-weighted average price) purchase mechanisms on qualifying days.
The agreement includes a provision that limits the investor’s ownership to no more than 4.99% of the company’s outstanding common stock at any time. The company also entered into a registration rights agreement, granting the investor customary rights to register the resale of shares acquired under the purchase agreement.
Cero Therapeutics is classified as an emerging growth company and is incorporated in Delaware. Its common stock is listed on NASDAQ under the symbol CERO, and its warrants are listed under the symbol CEROW.
All information in this article is based on statements from a press release and the company’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, CERo Therapeutics Holdings, Inc. has completed the first cohort of its Phase 1 clinical trial for its CER-1236 therapy targeting acute myeloid leukemia, with no dose-limiting toxicities observed. The company has administered a third infusion of CER-1236 to a patient in the same trial, aiming to gather further safety and dosing data. Additionally, CERo Therapeutics has amended its Securities Purchase Agreement, increasing the initial closing by $500,000, bringing the total to approximately $2.25 million. This adjustment reduces the size of subsequent closings, with the aggregate funding under the agreement remaining at up to $7 million. The company has also established its Series E convertible preferred stock, following a Certificate of Designations filing. Meanwhile, CERo Therapeutics is open to licensing deals or a potential sale as it awaits key data on its lead asset, according to a report by Axios. The Dose Escalation Safety Committee has approved the initiation of the second cohort in the leukemia trial, which will receive an increased starting dosage. These developments highlight CERo Therapeutics’ ongoing efforts in advancing its clinical trials and securing additional funding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.